Strategies to increase uptake of voluntary medical male circumcision among men aged 25-39 years in Nyanza Region, Kenya: Results from a cluster randomized controlled trial (the TASCO study).


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 24 09 2021
accepted: 04 10 2022
entrez: 3 2 2023
pubmed: 4 2 2023
medline: 8 2 2023
Statut: epublish

Résumé

Voluntary medical male circumcision (VMMC) for HIV prevention began in Nyanza Region, Kenya in 2008. By 2014, approximately 800,000 VMMCs had been conducted, and 84.9% were among males aged 15-24 years. We evaluated the impact of interpersonal communication (IPC) and dedicated service outlets (DSO) on VMMC uptake among men aged 25-39 years in Nyanza Region. We conducted a cluster randomized controlled trial in 45 administrative Locations (clusters) in Nyanza Region between May 2014 and June 2016 among uncircumcised men aged 25-34 years. In arm one, an IPC toolkit was used to address barriers to VMMC. In the second arm, men were referred to DSO that were modified to address their preferences. Arm three combined the IPC and DSO arms, and arm four was standard of care (SOC). Randomization was done at Location level (11-12 per arm). The primary outcome was the proportion of enrolled men who received VMMC within three months. Generalized estimating equations were used to evaluate the effect of interventions on the outcome. At baseline, 9,238 households with men aged 25-39 years were enumerated, 9,679 men were assessed, and 2,792 (28.8%) were eligible. For enrollment, 577 enrolled in the IPC arm, 825 in DSO, 723 in combined IPC + DSO, and 667 in SOC. VMMC uptake among men in the SOC arm was 3.2%. In IPC, DSO, and combined IPC + DSO arms, uptake was 3.3%, 4.5%, and 4.4%, respectively. The adjusted odds ratio (aOR) of VMMC uptake in the study arms compared to SOC were IPC aOR = 1.03; 95% CI: 0.50-2.13, DSO aOR = 1.31; 95% CI: 0.67-2.57, and IPC + DSO combined aOR = 1.31, 95% CI: 0.65-2.67. Using these interventions among men aged 25-39 years did not significantly impact VMMC uptake. These findings suggest that alternative demand creation strategies for VMMC services are needed to reach men aged 25-39 years. clinicaltrials.gov identifier: NCT02497989.

Identifiants

pubmed: 36735665
doi: 10.1371/journal.pone.0276593
pii: PONE-D-21-29151
pmc: PMC9897540
doi:

Banques de données

ClinicalTrials.gov
['NCT02497989']

Types de publication

Randomized Controlled Trial Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0276593

Subventions

Organisme : PEPFAR
Pays : United States
Organisme : CGH CDC HHS
ID : U01 GH000518
Pays : United States

Informations de copyright

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS Med. 2009 Sep;6(9):e1000109
pubmed: 19901974
J Acquir Immune Defic Syndr. 2014 May 1;66 Suppl 1:S37-45
pubmed: 24732820
Lancet. 2007 Feb 24;369(9562):657-66
pubmed: 17321311
PLoS One. 2017 Oct 5;12(10):e0185872
pubmed: 28982175
PLoS One. 2011 Apr 04;6(4):e18299
pubmed: 21483697
AIDS Behav. 2016 Nov;20(11):2529-2537
pubmed: 26424709
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
MMWR Morb Mortal Wkly Rep. 2012 Nov 30;61(47):957-61
pubmed: 23190568
Epidemiology. 2004 Mar;15(2):157-63
pubmed: 15127907
MMWR Morb Mortal Wkly Rep. 2013 Nov 29;62(47):953-7
pubmed: 24280914
AIDS. 2017 Apr 24;31(7):1025-1034
pubmed: 28350578
PLoS Med. 2011 Nov;8(11):e1001130
pubmed: 22140365
PLoS Med. 2005 Nov;2(11):e298
pubmed: 16231970
PLoS Med. 2011 Nov;8(11):e1001132
pubmed: 22140367
Am J Epidemiol. 1981 Dec;114(6):906-14
pubmed: 7315838
J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):66-70
pubmed: 17019365
JAMA. 2014 Aug 20;312(7):703-11
pubmed: 25042290

Auteurs

Jonathan M Grund (JM)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Frankline Onchiri (F)

Core for Biomedical Statistics, Seattle Children's Research Institute, Seattle, Washington, United States of America.

Edward Mboya (E)

Impact Research and Development Organization, Kisumu, Kenya.

Faith Ussery (F)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Paul Musingila (P)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Kisumu, Kenya.

Spala Ohaga (S)

Impact Research and Development Organization, Kisumu, Kenya.

Elijah Odoyo-June (E)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Kisumu, Kenya.

Naomi Bock (N)

Division of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Benard Ayieko (B)

Impact Research and Development Organization, Kisumu, Kenya.

Kawango Agot (K)

Impact Research and Development Organization, Kisumu, Kenya.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH